[ad_1] Lupin enter into licensing agreement with Valorum for biosimilar Armlupeg in US We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Drug maker Lupin on Monday said it has received approval from the US health regulator for a biosimilar indicated for the treatment of neutropenia in cancer patients. The US Food and Drug Administration (USFDA) has approved Armlupeg (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta…
[ad_1] Lupin secures USFDA nod for biosimilar Armlupeg We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link